Thursday, September 29, 2022


Biotechnology News Magazine

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

“We are pleased to be sharing a number of new clinical and preclinical analyses at ATC, including a real-world, retrospective analysis reflecting key health outcomes of our Phase 2 patients treated with FCR001 compared to a matched group of patients treated with standard of care,” said Scott Requadt, Chief Executive Officer of Talaris. “This study underscores the potential benefits to kidney function and cardiometabolic health experienced by patients who are able to avoid long-term immunosuppression.”

A conference call to provide an interim update on the FREEDOM-1 study, originally planned for June 8, 2022, has been rescheduled pending receipt of data from all participating sites and will now be held on June 30, 2022.

ATC Data Presentation Highlights

Real-world data comparison of matched controls to Phase 2 treated patients. In a poster presented at the 2022 ATC meeting, Talaris reported findings of a retrospective, real-world assessment of the safety and efficacy of FCR001 as compared with standard of care (SOC) immunosuppression. Medical records were used to identify 144 patients who received transplants contemporaneously and at the same institution as 36 of the 37 Phase 2 clinical trial participants, and who met the study’s inclusion and exclusion criteria, including age, HLA mismatch and BMI.

The analysis indicated that patients treated with FCR001 had no higher incidence of death, graft loss or biopsy-proven acute rejection than did patients on IS in the five years post-transplant. Kidney function, defined as estimated glomerular filtration rate (eGFR), was significantly higher in patients treated with FCR001 at five years (p=0.02), and key immunosuppression-related cardiometabolic complications were observed less frequently in patients treated with FCR001 compared to those on IS.

Phase 2 long-term follow-up shows consistent durability off IS. In an oral presentation at the 2022 ATC meeting, Talaris provided an update on the continued long-term follow-up of patients in its Phase 2 LDKT study. Talaris previously reported that 26 of 37 (70%) patients in its Phase 2 study achieved stable T-cell chimerism and were weaned off all chronic IS by approximately 12 months after their transplant. To date, all surviving patients weaned off IS remain IS- and rejection-free. Talaris has followed these patients from five to 12.8 years post-transplant. Six subjects have remained off IS > 10 years.

In the Phase 2 study, Talaris did not observe any correlation between the degree of HLA mismatch and the safety or efficacy measures in the study. Patients at all levels of HLA matching were able to discontinue chronic immunosuppression, with 19 out of 26 recipients (73%) who durably discontinued their chronic IS having an HLA match of three or less to their donor.

As of May 31, 2022, Talaris Therapeutics has accumulated over 250 patient-years of exposure to FCR001 in LDKT, and the safety profile observed in the Phase 2 patients remains generally consistent with that expected with kidney and allogeneic stem cell transplantation involving non-myeloablative conditioning.

COVID-19 outcomes among Phase 2 patients. In a poster presented at the 2022 ATC meeting, investigators at Northwestern University shared updated data on COVID-19 rates, effects of COVID-19 infection and antibody response to vaccination among evaluable patients in the Company’s Phase 2 study. Of the 23 durably chimeric patients off chronic IS, 18 were vaccinated, of whom 5 (28%) tested positive for COVID-19. None of these 18 patients lost chimerism as a result of their COVID-19 vaccination. Among the remaining 5 patients who were off all chronic IS but were unvaccinated, 3 (60%) tested positive for COVID-19. Among the 5 patients who remained on chronic IS, 4 of whom were vaccinated, 3 (60%) tested positive for COVID-19. COVID-19 infection did not lead to reduction in renal function for patients, and none of the COVID-19-infected patients were hospitalized or experienced acute kidney injury as a result of their infection.

As previously reported, post-vaccination antibody testing had been performed on 4 patients (3 durably chimeric, 1 not). These data showed that all 4 patients produced strong antibody responses to COVID-19 vaccination.

Identification of immune cells involved in sensitization. In a poster presented at the 2022 ATC meeting, Talaris reported findings from a study in animal models to discern the mechanisms of immune sensitization, which increases the risk of graft rejection for bone marrow and solid organ transplants. An examination of immune response to foreign cells in mice engineered to lack either T cell receptors or Fcγ receptors found that Fcγ-bearing macrophages and NK cells, and not T cells, mediate this type of immune rejection.

Potential urinary biomarker of immune quiescence. In an oral presentation at the 2022 ATC meeting, Talaris reported findings of urinary mRNA profiling that it performed in a subgroup of Phase 2 LDKT patients who were tolerized to their donated kidney, as well as in a biopsy-matched cohort of standard of care LDKT recipients on chronic IS. The analysis identified potential signals of greater immune quiescence in the kidneys of tolerized patients as compared to the standard of care cohort. These findings may provide further support that these patients have been tolerized to their donated kidney.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine